The AIPM brings together manufacturers of both original and generic medicines. However, the approaches and business models of member companies may vary, and each company has the right to protect its interests within the framework of current legislation. All disputes related to intellectual property should be resolved exclusively by competent authorities, such as courts, Rospatent, and the Federal Antimonopoly Service, in accordance with their authority.
The Association considers it important to express its position: the introduction of generic drugs into the market while a patent is still in effect, as well as before a court or authorized body's decision or ruling confirming the existence of other legal grounds for the introduction of a drug into circulation, can create legal uncertainty and contribute to the development of risky practices in the competitive environment, which may lead to a decrease in the sustainable availability of necessary medicines for patients. According to the Association, such steps do not fully comply with the principles of fair competition and weaken the trust in intellectual property institutions.
The Association's members are advised to take this approach into consideration when conducting a comprehensive assessment of the risks and opportunities associated with the introduction of new medicines to the market. Special attention should be paid to analyzing the potential consequences for emerging market practices and ensuring compliance with intellectual property rights. The implementation of a balanced and reasonable approach contributes to strengthening legal certainty, which is a key factor in ensuring the stable functioning of the pharmaceutical market and the entire drug supply system.
The Association draws attention to the fact that the activities of pharmaceutical companies involve a high degree of responsibility towards society. Providing objective information about their medicines, while avoiding the discrediting of competitors' products, should be an integral part of the marketing strategies of the Association's member companies. We are convinced that compliance with the ethical standards and requirements for the promotion of medicines established by current legislation, as well as internal industry standards, contributes to maintaining fair competition and ensuring patient safety.
The Association considers it important to express its position: the introduction of generic drugs into the market while a patent is still in effect, as well as before a court or authorized body's decision or ruling confirming the existence of other legal grounds for the introduction of a drug into circulation, can create legal uncertainty and contribute to the development of risky practices in the competitive environment, which may lead to a decrease in the sustainable availability of necessary medicines for patients. According to the Association, such steps do not fully comply with the principles of fair competition and weaken the trust in intellectual property institutions.
The Association's members are advised to take this approach into consideration when conducting a comprehensive assessment of the risks and opportunities associated with the introduction of new medicines to the market. Special attention should be paid to analyzing the potential consequences for emerging market practices and ensuring compliance with intellectual property rights. The implementation of a balanced and reasonable approach contributes to strengthening legal certainty, which is a key factor in ensuring the stable functioning of the pharmaceutical market and the entire drug supply system.
The Association draws attention to the fact that the activities of pharmaceutical companies involve a high degree of responsibility towards society. Providing objective information about their medicines, while avoiding the discrediting of competitors' products, should be an integral part of the marketing strategies of the Association's member companies. We are convinced that compliance with the ethical standards and requirements for the promotion of medicines established by current legislation, as well as internal industry standards, contributes to maintaining fair competition and ensuring patient safety.